Giant Biogene Holding Co., Ltd. (2367.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. The company also manufactures functional foods leveraging rare ginsenosides technology and provides medical devices. Its diverse product range, which includes specialized skincare, medical dressings, and nutritional supplements, is marketed predominantly under brand names such as Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. Established in 2000, Giant Biogene Holding Co., Ltd. maintains its headquarters in Xi'an, PRC.

Industry: Household & Personal Products
Sector: Consumer Defensive
Headquarters: CN
CEO: Jianya Yan
Listed since: Nov 4, 2022
Employees: 2,319

Market position

52-week range

Current HK$27.12

HK$24.20HK$65.70

Open: HK$27.12
Previous close: HK$27.08
Volume: 0; 0× average
Average volume: 5.39M; Average daily volume
Market cap: 28.79B HKD
Beta: 0.75; Market reference 1
50-day average: HK$27.916; -2.85% below average
200-day average: HK$31.2475; -13.21% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): 14.9×
P/B (TTM): 2.61×
P/S (TTM): 4.67×
Dividend yield: 5.12%

Profitability & efficiency

Gross margin: 79.07%
Operating margin: 31.69%
Net margin: 31.41%

Financial health

Debt / equity: 0×
Altman Z-score: 20.33
Piotroski F-score: 5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

5.52B CNY-0.37%

Operating income

2.12B CNY-8.14%

Net income

1.91B CNY-7.15%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	5.52B CNY	5.54B CNY	3.52B CNY	2.36B CNY	1.55B CNY
Cost of goods sold	1.09B CNY	991.9M CNY	577.01M CNY	369.21M CNY	198.15M CNY
Gross profit	4.43B CNY	4.55B CNY	2.95B CNY	2B CNY	1.35B CNY
Research and development	88.79M CNY	106.5M CNY	74.97M CNY	44.04M CNY	24.95M CNY
Selling, general, and administrative	2.22B CNY	2.16B CNY	1.26B CNY	817.44M CNY	353.14M CNY
Operating expenses	2.31B CNY	2.24B CNY	1.28B CNY	817.32M CNY	425.62M CNY
Interest income	167.68M CNY	111.35M CNY	47.49M CNY	13.16M CNY	9.41M CNY
Interest expense	302K CNY	239K CNY	112K CNY	21K CNY	—
Depreciation and amortization	74.17M CNY	31.62M CNY	34.18M CNY	27.63M CNY	23.07M CNY
Operating income	2.12B CNY	2.31B CNY	1.66B CNY	1.13B CNY	914.57M CNY
Net income	1.91B CNY	2.06B CNY	1.45B CNY	1B CNY	828.13M CNY